Supernus Pharmaceuticals, Inc. provided earnings guidance for the year 2024. For the year, the company expects total revenues (includes approximately $125 - $135 million of Trokendi XR and Oxtellar XR) of $580 million - $620 million, and Operating loss of $30 million - $0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.77 USD | -0.36% | -3.38% | -4.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.04% | 1.53B | |
+9.28% | 8.74B | |
-15.14% | 4.94B | |
+50.73% | 4.7B | |
+4.36% | 3.98B | |
-26.13% | 2.28B | |
+12.07% | 2.28B | |
+16.45% | 2.14B | |
-33.59% | 2.12B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024